CXI Healthcare Technology Group
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
CXI Healthcare Technology Group makes health supplements, capsules, tablets, granules, and teas, based on traditional Chinese herbal ingredients, and distributes those products primarily in China.
Its subsidiaries also supply raw materials such as cordyceps fungus and tea leaves through their own distribution network, and operate a skincare cosmetics line through major Chinese online platforms. Listed on KOSDAQ, Korea's tech and small-cap board, the company itself is a holding company that does not conduct direct operations, its Chinese subsidiaries and sub-subsidiaries carry out all business activities.
Summary is AI-generated and may contain errors · figures from DART filings
The holding company is incorporated in the Cayman Islands and controls its operating businesses through Chinese subsidiaries, a structure common among overseas-listed groups.
CXI Healthcare Technology Group in five facts
What does CXI Healthcare Technology Group do?
CXI Healthcare Technology Group makes health supplements, capsules, tablets, granules, and teas, based on traditional Chinese herbal ingredients, and distributes those products primarily in China.
Where is CXI Healthcare Technology Group listed and in which sector?
CXI Healthcare Technology Group (Korean name: 씨엑스아이) trades under KRX code 900120 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Financials sector, Diversified Financials.
How large is CXI Healthcare Technology Group?
Its market capitalisation was US$29.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were CXI Healthcare Technology Group's latest annual revenue and operating profit?
For fiscal year 2025, CXI Healthcare Technology Group reported revenue of US$224.2K, operating profit of US$37.9K and net income of US$49.6K, per its annual report on DART (data retrieved from DART on 2026-09-25). Revenue was down 21.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-25
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Auditor's report filedOct 20
- [Amended] Proxy solicitation reference documentOct 20
- [Amended] Notice of general shareholders' meetingOct 20
- [Amended] Material event report (equity acquisition)M&A · Oct 19 · 2 versions
- DisclosureOct 14
- Change of 30% or more in revenue or profit/loss structure (15% for large companies) (subsidiary)
CXI Healthcare Technology Group reported a subsidiary's separate results for the fiscal year ended Jun 2026: revenue of US$37M (−8% year on year), operating profit of US$4.39M (−49.9% year on year) and net income of US$4.25M (−47.9% year on year).
Earnings · Oct 8 - Change of 30% or more in revenue or profit/loss structure (15% for large companies) (subsidiary)
CXI Healthcare Technology Group reported a subsidiary's separate results for the fiscal year ended Jun 2026: an operating loss of US$4.58K (from a profit a year earlier) and a net loss of US$4.58K.
Earnings · Oct 8 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
CXI Healthcare Technology Group reported consolidated results for the fiscal year ended Jun 2026: revenue of US$37M (−14.2% year on year), operating profit of US$2.23M (−69.3% year on year) and net income of US$6.03M (−36.7% year on year).
Earnings · Oct 8 - Resolution to convene a general shareholders' meetingOct 8
- Proxy solicitation reference documentOct 8
- Notice of general shareholders' meetingOct 8
- Other market noticeOct 7
- Trading suspension liftedOct 2
- Report on securities held by executives/major shareholdersAug 31
- Report on large shareholdings (5% rule) (abbreviated)Aug 31
- Report on securities held by executives/major shareholdersAug 31
- Report on large shareholdings (5% rule) (abbreviated)Aug 31
- Report on securities held by executives/major shareholdersAug 31
- Report on large shareholdings (5% rule) (standard)Aug 31
- Securities issuance results (voluntary) (third-party placement)
CXI Healthcare Technology Group completed a third-party-placement issuance of 8,000,000 common shares on August 28, 2026, raising US$32.3M (funded via HKD 253,538,981.63) versus the originally planned US$34.8M, with the gap due to exchange-rate movement.
Capital raise · Aug 28 - Trading suspension (share consolidation/split registration)
Trading in CXI Healthcare Technology Group Limited common shares will be suspended from 2026-08-25 until the day before the change-of-listing date of the new share certificates, due to a share consolidation.
M&A · Aug 20 - [Amended] Material event report (equity acquisition)
CXI Healthcare Technology Group Limited amends its July 15, 2026 disclosure of its acquisition of Fujian Yongsheng Huoli Bioengineering Co., Ltd. (valued at US$225M in a gratuitous intra-group transfer with no cash consideration) to update the expected acquisition date from August 31, 2026 to August 19, 2026 following completion of registration.
M&A · Aug 19 - Supply contract signed (subsidiary)
CXI Healthcare Technology Group disclosed a subsidiary's supply contract with Huamei Haolian Medical Technology (Beijing) Co., Ltd., worth US$4.99M, about 13.56% of the subsidiary's recent annual revenue, running through Jul 2027.
Supply contract · Jul 27 - Material event report (rights offering)
CXI Healthcare Technology Group disclosed a private placement (third-party allotment) to raise US$32.4M, about 306.3% of its market value.
Capital raise · Jul 21 - Material event report (equity acquisition)
CXI Healthcare Technology Group Limited's board resolved on July 15, 2026 to acquire 100% of its sub-subsidiary Fujian Yingshenghuoli Bio-Engineering Co., Ltd. from its subsidiary Zhejiang Dingsheng Health Technology Group Co., Ltd. in a no-consideration transfer valued at US$212M, as part of an internal governance restructuring, with the transaction expected to complete on August 31, 2026.
M&A · Jul 16 - Securities issuance results (voluntary) (third-party placement)
CXI Healthcare Technology Group completed an overseas third-party-placement rights offering on July 9, 2026, issuing 5,500,000 common shares for US$4.29M (paid in as HKD 33,570,701.93), slightly below the originally planned US$4.38M due to exchange-rate movement between the board resolution date and the payment date.
Capital raise · Jul 9 - Material event report (rights offering)
CXI Healthcare Technology Group disclosed a private placement (third-party allotment) to raise US$4.25M, about 42.1% of its market value.
Capital raise · Jul 1 - Securities issuance results (voluntary) (third-party placement)Capital raise · Jun 12
- [Amended] Material event report (rights offering)
CXI Healthcare Technology Group updated the terms of a private placement (third-party allotment) to raise US$4.77M, about 46.2% of its market value.
Capital raise · Jun 11 · 2 versions - Trading suspension (share consolidation/split registration)M&A · May 7
- Change of largest shareholderOwnership change · Mar 12
- Securities issuance results (voluntary) (third-party placement)Capital raise · Mar 12
- [Amended] Material event report (rights offering)
CXI Healthcare Technology Group updated the terms of a private placement (third-party allotment) to raise US$3.59M, about 34.0% of its market value.
Capital raise · Mar 9 · 3 versions